SCHEMBL2221168

SCHEMBL2221168

Cc1nnc(-c2cccc(Br)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
DCTPP1 Q9H773 1/20 0.46
HSD17B1 P14061 1/20 0.46
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
GABRG2 P18507 3/20 0.41
GABRB3 P28472 3/20 0.41
GABRA5 P31644 3/20 0.41
GABRA3 P34903 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14873462 0.83 HSD17B1 (0.55) ALDH1A1MEN1KMT2AHSD17B1RAB9A
SCHEMBL12971 0.81 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ADCTPP1HSD17B1
SCHEMBL16636791 0.79 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AHSD17B1RAB9A
SCHEMBL368725 0.79 KDM4E (0.65) ALDH1A1MEN1KMT2AHDAC1HDAC2
SCHEMBL8045495 0.79 HDAC1 (0.46) ALDH1A1MEN1KMT2AHDAC1HDAC2
SCHEMBL460799 0.79 KDM4E (0.65) ALDH1A1MEN1KMT2ADCTPP1HSD17B1
SCHEMBL2288997 0.79 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AHSD17B1RAB9A
SCHEMBL3830634 0.79 RAB9A (0.46) ALDH1A1MEN1KMT2AHDAC1HDAC2
SCHEMBL17184845 0.77 CA1 (0.49) ALDH1A1HDAC1HDAC2DCTPP1RAB9A
SCHEMBL2421712 0.77 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AHSD17B1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed
WO-1995027692-A1 SUBTITUTED BIPHENYL TNF INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1995-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 ALDH1A1 1673/4885MEN1 1349/4885KMT2A 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.